I prefer to see thorough planning and details attended to in the upcoming precision medicine first in kind trials.
Overall Anavex is moving faster with a new and better approach than we have seen so far AD with two further indications for same drug running alongside.
I appreciate that and suspect the market will too. The risk/reward ratio must be one of the best right now and it seems to me it continues to improve.
Still for prudence I might take some profits before readouts.
News 
Market Data 
Discover 
